NEJM: Meridia worsens CV risks; FDA mulls its future
Patients with a history of cardiovascular (CV) conditions treated with sibutramine (Meridia, Abbott Laboratories) saw an increased risk of MI and nonfatal stroke, but not CV death, according to the results of a study published Sept. 2 in New England Journal of Medicine. (Source: Cardiovascular Business News)

Aussie doc accused of infecting 56 women with hepatitis C
An Australian doctor accused of infecting 56 women with hepatitis C while trying to conceal his own drug use has been ordered to stand trial. (Source: CTV Health)